Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
XSPRAY.STthis companyXspray Pharma AB (publ)	SEK 11.70	-7.05×	2×	0×	-7.84×	-98.3%	0.0%	0.0%	0.0%	-28.4%	-21.5%	-18.4%	0.28×	-0.1×	-9.6×	8.44×	0.0%	2	-0.43	2	C
ACE.STAscelia Pharma AB (publ)	SEK 0.53	-4.81×	3.67×	0×	-4.32×	-17.7%	0.0%	0.0%	0.0%	-76.7%	-73.4%	-19.8%	0.01×	0.67×	-13.46×	4.35×	0.0%	1	-8.91	2	C+
CANTA.STCantargia AB (publ)	SEK 1.55	7.08×	3.91×	3.28×	4.91×	1047.8%	99.0%	48.7%	46.4%	55.3%	57.9%	14.4%	0×	-1.83×	11.37×	9.8×	0.0%	5	3.27	4	A
IBT-B.STInfant Bacterial Therapeutics AB (publ)	SEK 72.80	-10.43×	6.46×	0×	-7.87×	-89.1%	0.0%	0.0%	0.0%	-61.9%	-58.8%	-10.6%	0×	2.11×	0×	2.72×	0.0%	2	-1.32	1	D+
IMMU.STMendus AB (publ)	SEK 5.88	-2.58×	0.5×	0×	-2.16×	-84.5%	0.0%	0.0%	0.0%	-19.4%	-19.9%	-28.0%	0.03×	0.4×	-36.63×	2.7×	0.0%	1	-0.16	2	B-
ITECH.STI-Tech AB	SEK 62.60	18.78×	3.58×	3.71×	9.05×	172.1%	28.2%	26.5%	19.7%	19.0%	20.3%	10.3%	0×	-2.82×	47.44×	9.11×	3.3%	5	14.46	4	A-
Peer median	—	-2.58×	3.67×	0×	-2.16×	-17.7%	0.0%	0.0%	0.0%	-19.4%	-19.9%	-10.6%	0×	0.4×	0×	4.35×	0.0%	2	-0.16	2	—